Bridge City Capital LLC Boosts Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Bridge City Capital LLC increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 7.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 94,471 shares of the medical instruments supplier’s stock after purchasing an additional 6,430 shares during the quarter. LeMaitre Vascular makes up approximately 2.3% of Bridge City Capital LLC’s portfolio, making the stock its 5th biggest holding. Bridge City Capital LLC owned 0.42% of LeMaitre Vascular worth $8,705,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of LMAT. Victory Capital Management Inc. raised its holdings in shares of LeMaitre Vascular by 23.3% in the 3rd quarter. Victory Capital Management Inc. now owns 53,060 shares of the medical instruments supplier’s stock worth $4,929,000 after purchasing an additional 10,011 shares during the period. Quest Partners LLC bought a new stake in shares of LeMaitre Vascular in the 3rd quarter worth approximately $265,000. Advisors Asset Management Inc. raised its holdings in shares of LeMaitre Vascular by 180.2% in the 3rd quarter. Advisors Asset Management Inc. now owns 1,852 shares of the medical instruments supplier’s stock worth $172,000 after purchasing an additional 1,191 shares during the period. Intech Investment Management LLC bought a new stake in shares of LeMaitre Vascular in the 3rd quarter worth approximately $377,000. Finally, Charles Schwab Investment Management Inc. grew its stake in LeMaitre Vascular by 6.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock valued at $17,789,000 after buying an additional 11,395 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price objective for the company. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Lake Street Capital lifted their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Finally, Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, LeMaitre Vascular currently has an average rating of “Moderate Buy” and an average price target of $95.25.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $83.49 on Friday. LeMaitre Vascular, Inc. has a 52-week low of $62.39 and a 52-week high of $109.58. The company has a market capitalization of $1.88 billion, a P/E ratio of 45.62, a P/E/G ratio of 2.22 and a beta of 0.89. The company has a fifty day moving average of $94.32 and a 200-day moving average of $94.47.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.49. The company had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. As a group, analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.96%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.16. The ex-dividend date is Thursday, March 13th. LeMaitre Vascular’s dividend payout ratio is 41.24%.

Insider Activity

In related news, insider Trent G. Kamke sold 2,009 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the transaction, the insider now owns 5,564 shares in the company, valued at $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.